Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-Hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer.

Next Previous
Trial Profile

An Open, Single and Multiple Dose, Efficacy and Safety Proof of Principle Study of Liproca Depot, a Controlled Release Formulation of 2-Hydroxyflutamide, Injected Into the Prostate in Patients With Localized Prostate Cancer.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxyflutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors LIDDS

    • Most Recent Events

    • 08 Feb 2018 According to a Lidds Pharma media release, results from this and the LPC-003 trials have been published in The Journal of Urology in December 2016.
    • 26 Apr 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 21 Jun 2009 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top